Physician profile
Syed Ali
NPI 1821165143
$182,654.53
in general payments reported to CMS, 2019-2025
45 companies · $43K in 2025
The $43K reported for 2025 was more than what 96% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $8,900 · 2021: $12K · 2022: $19K · 2023: $30K · 2024: $37K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Food and Beverage: $12K · Travel and Lodging: $6,985 · Consulting Fee: $1,650 · Education: $363.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $88,442.00 |
| Food and Beverage | $12,141.82 |
| Travel and Lodging | $6,984.57 |
| Consulting Fee | $1,650.00 |
| Education | $363.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $84,182.11 | 2020-2025 | Tremfya |
| Pfizer INC. | $44,800.72 | 2019-2024 | |
| Incyte Corporation | $40,938.02 | 2021-2025 | Opzelura |
| Mayne Pharma Commercial LLC | $2,247.61 | 2019-2025 | |
| Abbvie INC. | $1,754.89 | 2019-2025 | Skyrizi, Rinvoq, Botox |
| Galderma Laboratories, L.P. | $1,120.23 | 2019-2025 | Nemluvio, Aklief, Oracea |
| Amgen INC. | $1,094.06 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $1,040.79 | 2022-2025 | Bimzelx, Cimzia |
| Novartis Pharmaceuticals Corporation | $835.04 | 2021-2025 | |
| Lilly USA, LLC | $765.21 | 2021-2024 | Taltz, Olumiant, Ebglyss |
| Sun Pharmaceutical Industries INC. | $586.78 | 2019-2025 | Ilumya |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $582.77 | 2019-2024 | Cabtreo, Arazlo, Jublia |
| Regeneron Healthcare Solutions, INC. | $555.28 | 2022-2025 | Dupixent |
| Arcutis Biotherapeutics, INC. | $455.04 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $388.50 | 2019-2025 | Adbry, Anzupgo |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $257.10 | 2022-2024 | Sotyktu |
| Stryker Corporation | $168.89 | 2025 | Pangea |
| Genzyme Corporation | $168.57 | 2023-2025 | |
| Almirall LLC | $132.39 | 2022-2025 | Seysara |
| Allergan, INC. | $91.65 | 2021-2022 | |
| Paratek Pharmaceuticals, INC. | $87.86 | 2024-2025 | Nuzyra |
| Merz North America, INC. | $80.73 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $50.36 | 2019 | |
| Nabriva Therapeutics, Plc | $46.73 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $27.47 | 2025 | Spevigo |
| Dermira, INC. | $24.48 | 2020 | |
| Lnhc, INC | $24.39 | 2025 | Zelsuvmi |
| Mylan Pharmaceuticals INC. | $24.35 | 2019 | |
| Botanix Sb INC | $23.05 | 2025 | Sofdra |
| Verrica Pharmaceuticals INC. | $19.92 | 2025 | Ycanth |
| Helsinn Therapeutics (U.S.), INC. | $17.56 | 2025 | Valchlor |
| Epi Health, LLC | $16.41 | 2022 | |
| Revance Therapeutics, INC. | $14.41 | 2024 | Daxxify |
| Medimetriks Pharmaceuticals, INC. | $12.35 | 2022 | |
| Vyne Pharmaceuticals INC. | $11.40 | 2021 | |
| Kerecis Limited | $7.41 | 2022 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Syed Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.